By Jeffrey T. Lewis

 

Vertex Pharmaceuticals Inc. reported profit increased in the fourth quarter after sales of its Trikafta cystic fibrosis medication rose.

The Boston-based pharmaceuticals maker said net income rose to $770.1 million from $604 million in the same period a year earlier. Earnings per share reached $3.00 from $2.30 a year earlier and adjusted earnings per share rose to $3.37 from $2.51. Net product revenue increased to $2.07 billion in the quarter, from $1.63 billion a year earlier.

Revenue from Trikafta, by far the company's biggest seller, rose to $1.69 billion from $1.09 billion a year earlier. Revenue from the company's next-biggest seller in the fourth quarter, Kalydeco, fell to $152 million from $193 million.

The company reported full-year 2021 product revenue of $7.57 billion, beating its guidance from the third quarter earnings report of $7.4 billion to $7.5 billion. For 2022, Vertex issued product revenue guidance of $8.4 billion to $8.6 billion.

 

Write to Jeffrey T. Lewis at jeffrey.lewis@wsj.com

 

(END) Dow Jones Newswires

January 26, 2022 16:41 ET (21:41 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Vertex Pharmaceuticals Charts.
Vertex Pharmaceuticals (NASDAQ:VRTX)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Vertex Pharmaceuticals Charts.